health
Five-trial analysis finds lower pooled mortality with ATTR-CM treatments
A medRxiv preprint pooling five phase III trials reports lower all-cause mortality and better functional and health-status outcomes with disease-modifying treatments for transthyretin amyloid cardiomyopathy. Exploratory subgroup results found smaller effects on several non-mortality measures among patients taking a background stabilizer.